 |
Beyond Biotech - the podcast from LabiotechAuthor: Labiotech
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane. Language: en-us Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
How Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
Episode 189
Thursday, 19 March, 2026
Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, and Clarissa Koch, the company's Chief Scientific Officer.Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine, demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised.We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges.01:33: Meet Koenraad Wiedhaup03:13: Meet Clarissa Koch04:16: Leyden Labs' origin story06:21: Mucosal protection platform explained08:57: Complementing existing vaccines11:47: Science of mucosal immunity13:24: PanFlu lead candidate overview16:42: Key findings from recent publication22:02: Funding and future preparednessInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Seven biotech companies to know in the NetherlandsThe Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 Influenza solution deals pile up as pandemic preparedness increases
